We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-10.25%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.19B
AUM Growth
-$1.8B
Cap. Flow
-$1.09B
Cap. Flow %
-34.19%
Top 10 Hldgs %
52.73%
Holding
142
New
9
Increased
15
Reduced
47
Closed
31

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$32.3M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$32.3M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$30.9M
4
LLY icon
Eli Lilly
LLY
+$30M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$24.5M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$143M
2
APLS
Apellis Pharmaceuticals
APLS
+$52.9M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$39.4M
4
NVRO
NEVRO CORP.
NVRO
+$34.5M
5
TVTX icon
Travere Therapeutics
TVTX
+$32.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.5%
2 Financials 0.29%
3 Consumer Discretionary 0.04%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB icon
76
Nuvation Bio
NUVB
$2.27B
$5.73M 0.18%
1,769,701
– –
ATNX
77
DELISTED
Athenex, Inc. Common Stock
ATNX
$5.54M 0.17%
676,623
– –
ACRS icon
78
Aclaris Therapeutics
ACRS
$715M
$4.76M 0.15%
341,239
-42,000
-11% -$589K
NBTX
79
Nanobiotix
NBTX
$1.95B
$4.03M 0.13%
1,059,800
– –
QTNT
80
DELISTED
Quotient Limited Ordinary Shares
QTNT
$3.89M 0.12%
405,020
– –
ATXS
81
DELISTED
Astria Therapeutics
ATXS
$3.84M 0.12%
1,281,197
– –
PYXS icon
82
Pyxis Oncology
PYXS
$186M
$3.64M 0.11%
1,528,812
– –
MGNX icon
83
MacroGenics
MGNX
$235M
$3.62M 0.11%
1,227,202
-332,587
-21% -$1.75M
TYRA icon
84
Tyra Biosciences
TYRA
$1.85B
$3.54M 0.11%
494,403
– –
CLOV icon
85
Clover Health Investments
CLOV
$2.22B
$3.21M 0.1%
1,500,000
– –
YMAB
86
DELISTED
Y-mAbs Therapeutics
YMAB
$3.21M 0.1%
+212,018
New +$2.47M
SNCE
87
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$3.02M 0.09%
75,000
– –
ABSI icon
88
Absci
ABSI
$1.16B
$2.97M 0.09%
894,346
-296,606
-25% -$1.47M
NVNO
89
enVVeno Medical
NVNO
$6.94M
$2.95M 0.09%
22,332
– –
FLNA
90
PUT
Filana Therapeutics
FLNA
$41.6M
$2.81M 0.09%
+100,000
New +$2.53M
FUSN
91
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$2.62M 0.08%
1,052,445
-174,572
-14% -$802K
HYPR icon
92
Hyperfine
HYPR
$88.7M
$2.53M 0.08%
1,134,388
-365,612
-24% -$1.08M
ABOS icon
93
Acumen Pharmaceuticals
ABOS
$153M
$2.39M 0.07%
508,532
-88,410
-15% -$332K
RLMD icon
94
Relmada Therapeutics
RLMD
$542M
$2.3M 0.07%
121,350
-30,000
-20% -$654K
DRIO icon
95
DarioHealth
DRIO
$52.3M
$2.01M 0.06%
16,393
– –
FULC icon
96
Fulcrum Therapeutics
FULC
$240M
$1.44M 0.05%
294,118
– –
PEAR
97
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$1.39M 0.04%
900,548
-25,684
-3% -$100K
RACE icon
98
Ferrari
RACE
$67.7B
$1.14M 0.04%
6,200
– –
SONX
99
DELISTED
Sonendo, Inc.
SONX
$1.11M 0.03%
648,505
-20,000
-3% -$53.4K
ZY
100
DELISTED
Zymergen Inc. Common Stock
ZY
$1.09M 0.03%
883,332
– –
2 3
4
5 6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Perceptive Advisors held 142 positions worth $3.19B, down 36% from $4.99B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Perceptive Advisors withdrew a net $1.09B in Q2 2022, closing 31 positions and reducing 47 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $143M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 82% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Perceptive Advisors opened a new position in Seagen Inc. Common Stock worth $39.6M.

  • Perceptive Advisors's largest Q2 2022 buy was Seagen Inc. Common Stock: 224,000 shares worth $39.6M.
  • Perceptive Advisors added most to LYRA THERAPEUTICS INC in Q2 2022, an estimated $32.3M increase.
  • Perceptive Advisors's biggest Q2 2022 reduction was Apellis Pharmaceuticals, cutting an estimated $52.9M.
  • Perceptive Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, selling an estimated $143M.
  • Perceptive Advisors's ten largest holdings make up 53% of its $3.19B portfolio in Q2 2022.
  • Perceptive Advisors opened 9 new positions and closed 31 in Q2 2022.
  • Perceptive Advisors's portfolio value fell 36% quarter-over-quarter to $3.19B.

Based on Perceptive Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.